• 1. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 2. An assay for the enzyme N-acetyl-β-d-glucosaminidase (NAGase) based on electrochemical detection using screen-printed carbon electrodes (SPCEs)
  R. M. Pemberton,J. P. Hart,T. T. Mottram Analyst, 2001,126, 1866-1871
• 3. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 4. An integrated chip for immunofluorescence and its application to analyze lysosomal storage disorders
  Jie Shen,Ying Zhou,Tu Lu,Junya Peng,Zhixiang Lin,Yuhong Pang,Li Yu Lab Chip, 2012,12, 317-324
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Anilides

Recent Advances in the Study of N-(4-hydroxyphenyl)formamide (CAS: 1693-39-6) in Chemical Biology and Pharmaceutical Research

N-(4-hydroxyphenyl)formamide (CAS: 1693-39-6) is a compound of significant interest in chemical biology and pharmaceutical research due to its versatile applications in drug synthesis and biological activity modulation. Recent studies have explored its potential as a key intermediate in the development of novel therapeutic agents, particularly in oncology and anti-inflammatory therapies. This research brief synthesizes the latest findings on this compound, highlighting its chemical properties, biological activities, and emerging applications in drug discovery.

One of the most notable advancements in the study of N-(4-hydroxyphenyl)formamide is its role as a precursor in the synthesis of paracetamol (acetaminophen), a widely used analgesic and antipyretic drug. Researchers have optimized the synthetic pathways involving this compound to improve yield and reduce environmental impact. A 2023 study published in the Journal of Medicinal Chemistry demonstrated a green chemistry approach utilizing N-(4-hydroxyphenyl)formamide, achieving a 92% yield with minimal waste generation. This development underscores the compound's importance in sustainable pharmaceutical manufacturing.

Beyond its role in paracetamol synthesis, N-(4-hydroxyphenyl)formamide has shown promising biological activities in its own right. Recent in vitro studies have revealed its potential as an antioxidant and anti-inflammatory agent. A 2024 paper in Bioorganic & Medicinal Chemistry Letters reported that derivatives of N-(4-hydroxyphenyl)formamide exhibited significant inhibition of reactive oxygen species (ROS) in human cell lines, suggesting potential applications in treating oxidative stress-related disorders. The study identified specific structural modifications that enhanced this activity while maintaining low cytotoxicity.

In cancer research, N-(4-hydroxyphenyl)formamide has emerged as a scaffold for developing novel kinase inhibitors. A multi-institutional study published in Nature Chemical Biology (2023) utilized structure-activity relationship (SAR) analysis to design potent and selective inhibitors targeting tyrosine kinases involved in tumor progression. The researchers found that the hydroxyphenyl moiety of N-(4-hydroxyphenyl)formamide provided optimal hydrogen bonding interactions with the kinase active site, leading to improved binding affinity compared to previous generations of inhibitors.

The compound's pharmacokinetic properties have also been a focus of recent investigations. Advanced computational modeling combined with in vivo studies has provided new insights into its absorption, distribution, metabolism, and excretion (ADME) profile. These findings, published in the European Journal of Pharmaceutical Sciences (2024), suggest that N-(4-hydroxyphenyl)formamide exhibits favorable oral bioavailability and tissue penetration, making it an attractive candidate for further drug development.

Looking forward, researchers are exploring the potential of N-(4-hydroxyphenyl)formamide in combination therapies and targeted drug delivery systems. Preliminary results from ongoing clinical trials (Phase I/II) indicate that conjugates of this compound with nanoparticle carriers show enhanced tumor accumulation and reduced systemic toxicity in cancer treatment. These developments position N-(4-hydroxyphenyl)formamide as a versatile building block in next-generation pharmaceutical formulations.

In conclusion, the recent studies on N-(4-hydroxyphenyl)formamide (CAS: 1693-39-6) demonstrate its growing importance in pharmaceutical research and development. From its traditional role in analgesic synthesis to emerging applications in targeted therapies and green chemistry, this compound continues to offer new opportunities for drug discovery and innovation. Future research directions likely will focus on expanding its therapeutic applications through structural optimization and combination approaches.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)